Multicenter clinical study with genetic polymorphisms analysis for the individualized antiemetic treatment.

2015 Fiscal Year Final Research Report

• Project/Area Number: 26860110
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy
• Research Institution: University of Shizuoka
• Principal Investigator: Tsuji Daiki 静岡県立大学, 薬学部, 助教 (90565615)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: グラニセトロン / パロノセトロン / アプレピタント / 遺伝子多型 / 制吐療法 / 薬物応答性 / オーダーメイド医療

Outline of Final Research Achievements

This study evaluated the potential roles of pharmacogenomic polymorphisms in antiemetic treatment resistance in cancer patients previously enrolled in a randomized controlled trial (granisetron vs. palonosetron). A total of 156 patients treated with cisplatin-based chemotherapy were evaluated for their responses.
In the granisetron group, the investigation of genetic polymorphisms on the pharmacokinetics of antiemetics showed that ABCB1 2677G>T/A and 3435C>T were associated with CR in overall phase. Multivariable logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR. No association was found in palonosetron group.
The investigation of genetic polymorphisms on the pharmacodynamics of antiemetics showed that ERCC1 8092 G>T and HT3D 107G>C were associated with CR in acute phase. The multivariate logistic regression analysis revealed that the ERCC1 8092TT and female were significant predictors of CR in acute phase.

Free Research Field

医療薬学　臨床薬理学